Workflow
*ST双成: 北京市中伦律师事务所关于海南双成药业股份有限公司2025年限制性股票与股票期权激励计划的法律意见书

Core Viewpoint - The legal opinion letter from Beijing Zhonglun Law Firm confirms that Hainan Shuangcheng Pharmaceutical Co., Ltd. meets the conditions for implementing the 2025 Restricted Stock and Stock Option Incentive Plan, and the plan complies with relevant laws and regulations [1][22]. Group 1: Conditions for Implementing the Incentive Plan - The company is legally established and listed on the Shenzhen Stock Exchange, having completed the necessary registration and approvals [4][5]. - The company does not fall under any prohibitive conditions outlined in the Management Measures for Stock Incentives [5][6]. Group 2: Content of the Incentive Plan - The incentive plan aims to enhance the company's governance structure and motivate key personnel to align their interests with those of shareholders, promoting long-term development [6][22]. - The plan includes provisions for the types of stock involved, the number of shares to be granted, and the distribution among different categories of employees, totaling up to 20 million shares, which is 4.82% of the company's total equity [8][9]. Group 3: Procedures for Implementing the Incentive Plan - The company has completed necessary procedures, including board reviews and the drafting of relevant documents, but still needs to submit the plan for shareholder approval [15][18]. - The plan requires a two-thirds majority vote from shareholders, excluding those with conflicts of interest, to be implemented [15][21]. Group 4: Impact on Company and Shareholders - The plan is designed to benefit the company and all shareholders, ensuring that it does not harm their interests and complies with legal requirements [20][22]. - The company has committed not to provide financial assistance to incentive recipients, ensuring that funding comes from the recipients themselves [19][20].